MENU

Trial Balance Trust Receipt as of November 30, 2020

Trial Balance Regular Agency Fund as of November 30, 2020

Trial Balance Internally Generated Income as of October 31, 2020

Trial Balance Internally Generated Income as of November 30, 2020

Trial Balance Trust Receipt as of October 31, 2020

Trial Balance Business Type Income as of October 31, 2020

Statement of Comparison of Budget and Actual Amount Consolidated-All Funds for the year ended December 31, 2020 (in thousand pesos0

Statement of Changes in Net Assets/Equity Regular Agency Fund as of December 31, 2020

Statement of Cash Flows Consolidated-All Funds for the year ended December 31, 2020

Pre-Closing Trial Balance Regular Agency Fund as of December 31, 2020

Pre-Closing Trial Balance Internally Generated Income as of December 31, 2020

Statement of Changes in Net Assets /Equity Business Type Income As of December 31, 2020 

Statement of Cash Flows Consolidated-All Funds for the Year ended December 31, 2019 and 2020

Post-Closing Trial Balance Internally Generated Income as of December 31, 2020

Pre-Closing Trial Balance Business Type Income as of December 31, 2020

Notes to Financial Statements for the Year ended December 31, 2020

FY 2021 Monthly Disbursement Program (In thousand pesos)

FY 2021 Monthly Disbursement Program (In thousand pesos)

FY 2021 Financial Plan (in thousand pesos)

Post-Closing Trial Balance Trust Receipt as of December 31, 2020

Detailed Statement of Financial Position Regular Agency Fund as of December 31, 2020

Detailed Statement of Financial Position Internally Generated Income as of December 31, 2021

Detailed Statement of Financial Position Consolidated-All Funds as of December 31, 2020

Detailed Statement of Financial Position Business Type Income as of December 31, 2020

Detailed Statement of Financial Performance Trust Receipt for the period ending December 31, 2020

Detailed Statement of Financial Performance Regular Agency Fund for the period ending December 31, 2020

Detailed Statement of Financial Performance Internally Generated Income for the Period ending December 31, 2020

Detailed Statement of Financial Performance Consolidated-All Funds for the Year Ended December 31, 2020

Detailed Statement of Financial Performance Business Type Income for the period Ending December 31, 2020

Detailed Statement of Financial Performance December 31, 2019 and 2020 (2)

Detailed Statement of Financial Performance December 31, 2019 and 2020

Detailed Statement of Financial Performance December 31, 2019 and December 31, 2020

Detailed Statement of Cash Flows Trust Receipt for the Period January 01, 2020 to December 31, 2020

Detailed Statement of Cash Flows Regular Agency Fund for the Period January 01, 2020 to December 31, 2020

Detailed Statement of Cash Flows Internally Generated Income for the Period January 01, 2020 to December 31, 2020

Detailed Statement of Cash Flows Business Type Income for the Period January 01, 2020 to December 31, 2020

Detailed Statement of Cash Flows Business Type Income December 31, 2020

Condensed Statement of Financial Position Trust Receipt as of December 31, 2020

Condensed Statement of Financial Position Business Type Income

Condensed Statement of Financial Performance Trust Receipt for the period ending December 31, 2020

Condensed Statement of Financial Performance Initially Generated Income for the period ending December 31, 2020

Condensed Statement of Financial Performance Consolidated-All Funds for the Year Ended December 31, 2020

Condensed Statement of Financial Performance Business Type Income for the period ending December 31, 2020

Condensed Statement of Cash Flows Trust Receipt for the period January 01, 2020 to December 31, 2020

Condensed Statement of Cash Flows Trust Receipt December 31, 2020

Condensed Statement of Cash Flows Regulary Agency Fund for the Period January 01, 2020 to December 31, 2020

Condensed Statement of Cash Flows Regular Agency Fund December 31, 2020

Condensed Statement of Cash Flows Internally Generated Income for the Period January 01, 2020 to December 31, 2020

Condensed Statement of Cash Flows Internally Generated Income December 31, 2020

Condensed Statement of Cash Flows Business Type Income for the Period January 01, 2020 to December 31, 2020

Condensed Statement of Cash Flows Business Type Income December 31, 2020

Trial Balance Trust Receipt as of August 31, 2020

Trial Balance Regular Agency Fund as of August 31, 2020

Trial Balance Internally Generated Income as of August 31, 2020

Trial Balance Business Type Income as of August 31, 2020

List of Allotments and Sub-Allotments as at the Quarter Ending June 30, 2020

Trial Balance Trust Receipt as of July 31, 2020

Trial Balance Regular Agency Fund as of July 31, 2020

Trial Balance Internally Generated Income as of July 31, 2020

Trial Balance Business Type Income as of July 31, 2020

Condensed Statement of Cash Flows Drugs and Medicines Revolving Funds - Drugs and Medicines - N.B.C. 321 For the Period June 01, 2020 to June 30, 2020

Condensed Statement of Cash Flows Internally Generated Income For the Period June 01, 2020 to June 30, 2020

Condensed Statement of Cash Flows Regular Agency Fund for the Period June 01, 2020 to June 30, 2020

Condensed Statement of Cash Flows Trust Receipt for the Period June 01, 2020 to June 30, 2020

Condensed Statement of Financial Performance Business Type Income - Off-Budgetary Funds - Revolving Funds - Drugs and Medicines Revolving Funds - Drugs and Medicines - N.B.C. 321 for the period ending June 30, 2020

Condensed Statement of Financial Performance Internally Generated Income for the period ending June 30, 2020

Condensed Statement of Financial Performance Regular Agency Fund for the period Ending June 30, 2020

Condensed Statement of Financial Performance Trust Receipt for the Period ending June 30, 2020

Condensed Statement of Financial Position Business Type Income - Off-Budgetary Funds - Revolving Funds - Drugs and Medicines Revolving Funds - Drugs and Medicines - N.B.C. 321 as of June 30, 2020

Condensed Statement of Financial Position Internally Generated Income as of June 30, 2020

Condensed Statement of Financial Position Regular Agency Fund as of June 30, 2020

Condensed Statement of Financial Position Trust Receipt as of June 30, 2020

Detailed Statement of Cash Flows Drugs and Medicines Revolving Funds - Drugs and Medicines - N.B.C. 321 For the Period June 01, 2020 to June 30, 2020

Detailed Statement of Cash Flows Internally Generated Income For the Period June 01, 2020 to June 30, 2020

Detailed Statement of Cash Flows Regular Agency Fund For the Period June 01, 2020 to June 30, 2020

Detailed Statement of Cash Flows Trust Receipt for the Period June 01, 2020 to June 30, 2020

Detailed Statement of Financial Performance Business Type Income - Off-Budgetary Funds - Revolving Funds - Drugs and Medicines Revolving Funds - Drugs and Medicines - N.B.C. 321 - For the period ending June 30, 2020

Detailed Statement of Financial Performance Internally Generated Income For the period Ending June 30, 2020

Detailed Statement of Financial Performance Regular Agency Fund for the Period Ending June 30, 2020

Detailed Statement of Financial Performance Trust Receipt for the Period Ending June 30, 2020

Detailed Statement of Financial Position Business Type Income - Off-Budgetary Funds - Revolving Funds - Drugs and Medicines Revolving Funds - Drugs and Medicines - N.B.C. 321 as of June 30, 2020

Detailed Statement of Financial Position Internally Generated Income as of June 30, 2020

Detailed Statement of Financial Position Regular Agency Fund as of June 30, 2020

Detailed Statement of Financial Position Trust Receipt as of June 30, 2020

Statement of Changes in Net Assets/Equity Internally Generated Income as of June 30, 2020

Statement of Changes in Net Assets/Equity Trust Receipt as of June 30, 2020

Statement of Changes in Net Assets/Equity Regular Agency Fund as of June 30, 2020

Statement of Changes in Net Assets/Equity Business Type Income - Off-Budgetary Funds - Revolving Funds - Drugs and Medicines Revolving Funds - Drugs and Medicines - N.B.C . 321 as of June 30, 2020

Trial Balance Business Type Income as of June 30, 2020

Trial Balance Internally Generated Income as of June 30, 2020

Trial Balance Regular Agency Fund as of June 30, 2020

Trial Balance Trust Receipt as of June 30, 2020

Trial Balance Trust Receipt as of May 31, 2020

Trial Balance Regular Agency Fund as of May 31, 2020

Trial Balance Internally Generated Income as of May 31, 2020

Trial Balance Business Type Income as of May 31, 2020

Trial Balance Trust Receipt as of April 30, 2020

Trial Balance Business Type Income as of April 30, 2020

Trial Balance Regular Agency Fund as of April 30, 2020

Trial Balance Internally Generated Income as of April 30, 2020 

Trial Balance Trust Receipt as of March 31, 2020

Trial Balance Regular Agency Fund as of March 31, 2020

Trial Balance Internally Generated Income as of March 31, 2020

Trial Balance Business Type Income as of March 31, 2020

Statement of Changes in Net Assets/Equity Trust Receipt as of March 31, 2020

Statement of Changes in Net Assets/Equity Business Type Income as of March 31, 2020

Statement of Changes in Net Assets/Equity Regular Agency Fund as of March 31, 2020

Statement of Changes in Net Assets/Equity Internally Generated Income as of March 31, 2020

For Off-Budgetary Funds

For Off-Budgetary Funds

Detailed Statement of Financial Position Trust Receipt as of March 31, 2020

Detailed Statement of Financial Position Regular Agency Fund as of March 31, 2020

Detailed Statement of Financial Position Internally Generated Income As of March 31, 2020

Detailed Statement of Financial Position Business Type Income as of March 31, 2020

Detailed Statement of Financial Performance Trust Receipt for the Period ending March 31, 2020

Detailed Statement of Financial Performance Regular Agency Funding For the Period ending March 31, 2020

Detailed Statement of Financial Performance Internally Generated Income for the Period ending March 31, 2020

Detailed Statement of Financial Performance Business Type Income For the period ending March 31, 2020 

Detailed Statement of Cash Flows Specific Budgets of National Government Agencies for the Period Jan. 1 to March 31, 2020 

Detailed Statement of Cash Flows For the Period Jan 1 to March 31, 2020 

Detailed Statement of Cash Flows Hospital Retained Income Applicable to All DOH-Retained Hospitals for the Period Jan. 1 to March 31, 2020

Detailed Statement of Cash Flows Drugs and Medicines Revolving Funds - Drugs and Medicines - N.B.C. 321 For the Period Jan 1 to March 31, 2020

Condensed Statement of Financial Position Trust Receipt as of March 31, 2020

Condensed Statement of Financial Position Regular Agency Fund as of March 31, 2020

Condensed Statement of Financial Position Internally Generated Income as of March 31, 2020

Condensed Statement of Financial Position Internally Generated Income

Condensed Statement of Financial Position Business Type Income as of March 31, 2020

Condensed Statement of Financial Performance Trust Receipt For the Period ending March 31, 2020

Condensed Statement of Financial Performance Regular Agency Fund For the Period ending March 31, 2020

Condensed Statement of Financial Performance Internally Generated Income For the Period ending March 31, 2020

Condensed Statement of Financial Performance Business Type Income For the Period Ending March 31, 2020

Condensed Statement of Cash Flows Specific Budgets of National Government Agencies for the Period Jan. 1 to March 31, 2020

Condensed Statement of Cash Flows for the Period Jan. 1 to March 31, 2020

Condensed Statement of Cash Flows Hospital Retained Income Applicable to all DOH-Retained Hospitals for the Period Jan. 1 to March 31, 2020

Condensed Statement of Cash Flows Drugs and Medicines Revolving Funds -Drugs and Medicines - N.B.C. 321 for the Period January 1 to March 31, 2020

List of Allotments and Sub-Allotments as of the Quarter Ending March 31, 2020